Gallant Achieves FDA "Technical Section Complete" for Reasonable Expectation of Effectiveness, Advancing First Ready-to-Use Stem Cell Therapy

• The product is sonruvetcel suspension for injection – a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell therapy for cats with refractory feline chronic gingivostomatitis (FCGS).
• The U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) agreed that Gallant's data provides a reasonable expectation of effectiveness (RXE), a key requirement in the conditional approval process.
• RXE technical section completion is a significant milestone, keeping the therapy on track for conditional FDA approval in early 2026 and potentially becoming the first FDA-approved ready-to-use stem cell therapy in veterinary medicine.

SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Gallant, an animal health biotechnology company pioneering ready-to-use stem cell therapies for pets, today announced a key regulatory milestone. The U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) has issued a complete letter for the Reasonable Expectation of Effectiveness (RXE) technical section to support the conditional approval of Gallant's first ready-to-use stem cell therapy for refractory feline chronic gingivostomatitis (FCGS). With this regulatory step complete, Gallant is moving closer to delivering an entirely new category of medicine to veterinary clinics that targets disease at its source.

The product under review is Gallant's investigational new animal drug (INAD), sonruvetcel suspension for injection – a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell therapy developed specifically for cats with refractory FCGS. These cats suffer from severe oral pain and reduced quality of life, and with no therapeutic options available, many are ultimately euthanized. Gallant's cells are sourced from healthy, specific-pathogen free, FDA-qualified feline donors and manufactured under current Good Manufacturing Practice (cGMP) conditions, with potency established for FCGS. Conditional approval is targeted for early 2026, which could make it the first FDA-approved, ready-to-use stem cell therapy in veterinary medicine.

"Completion of the RXE technical section marks a foundational milestone for Gallant's uterine-derived platform of allogeneic mesenchymal stromal cell therapies—and the potential first ready-to-use stem cell therapy in veterinary medicine," said Dr. Valentine Williams, Senior Vice President of Clinical Development and Strategy at Gallant. "For many of us at Gallant, pioneering a gold-standard regenerative medicine platform has been a career-long ambition, serving beloved pets and enriching the lives of those who care for them. This success not only validates that vision but also demonstrates our ability to navigate the regulatory pathway for a pipeline of products that are leading the industry into the regenerative medicine era—an era focused on more than just managing clinical symptoms."

Gallant's therapy for refractory FCGS is being reviewed by FDA-CVM for conditional approval, allowing earlier access to a life-changing therapy where currently no options exist. If granted, conditional approval will allow veterinarians to begin prescribing and using the product in everyday practice in this underserved population of cats.

"This milestone represents a major leap forward in our mission to make stem cell therapies accessible to every pet in need," said Dr. Linda Black, CEO of Gallant. "We're pioneering FDA-approved regenerative therapies designed to be practical and transformative—readily available, delivered through a simple intravenous injection, and aimed at treating the root cause rather than just the symptoms. We are entering the regenerative medicine era—and proud to be leading the way."

Gallant is actively advancing a pipeline of ready-to-use stem cell therapies addressing both prevalent and underserved conditions in cats and dogs. In addition to refractory FCGS, clinical trials are ongoing or have been completed for feline osteoarthritis, chronic kidney disease, and canine diseases such as osteoarthritis and atopic dermatitis. Learn more at https://www.gallant.com/.

About Gallant

Gallant is an animal health biotechnology company creating a new category of veterinary medicine with a pipeline of ready-to-use stem cell therapies targeting the root causes of diseases in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible—moving beyond symptom management to restoring health at the source. Learn more at https://www.gallant.com/.

Media Contact:
Galyna Danylenko
+1 (443) 254-7567
[email protected]

SOURCE Gallant